Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000

被引:34
作者
Scott, P
Arnold, E
Evans, B
Pozniak, A
Moyle, G
Shahmenesh, M
White, D
Shirley, J
Cane, P
Pillay, D
机构
[1] Birmingham Heartlands Hosp, Dept Sexual Med, Birmingham B9 5ST, W Midlands, England
[2] Univ Hosp NHS Trust Birmingham, Birmingham, W Midlands, England
[3] Chelsea & Westminster Hosp, Dept HIV & GUM, London, England
[4] Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, HIV Div, London NW9 5EQ, England
[5] Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Stat Unit, London NW9 5EQ, England
[6] PHLS, Antiviral Susceptibil Reference Unit, Birmingham, W Midlands, England
关键词
HIV-1; resistance; surveillance;
D O I
10.1093/jac/dkh102
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To establish a surveillance programme for HIV drug resistance within the UK covering the years from 1998 to 2000, following the introduction of triple combination antiretroviral therapy. Methods: Sentinel sites included large, medium sized and small clinical centres. Data were analysed until December 2000. Results: Of nearly 300 samples tested, results from 91, 92 and 92 patients, respectively in 1998, 1999 and 2000, who were receiving HIV therapy with a viral load >2000 copies/mL, the majority had viruses with some degree of drug resistance. Overall, the presence of any resistance increased between 1998 and 1999, and fell again in 2000 (69% versus 88% versus 55%). However, major differences were observed between drug classes, such that non-nucleoside analogue reverse transcriptase inhibitor (NNRTI) resistance rose dramatically over the period studied. We show that this correlated with increased NNRTI prescribing. Furthermore, an overall increase in prevalence of viruses with resistance to one or more drugs within all three available classes was observed. A higher prevalence of drug resistance was observed in patients from smaller clinical centres. Conclusions: This is the first such sentinel surveillance dataset from the UK, and is unique in correlating these data with national antiretroviral prescribing patterns. Our findings are relevant to the increased transmission of HIV drug resistance observed over this period.
引用
收藏
页码:469 / 473
页数:5
相关论文
共 19 条
[1]   Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy [J].
Bacheler, LT ;
Anton, ED ;
Kudish, P ;
Baker, D ;
Bunville, J ;
Krakowski, K ;
Bolling, L ;
Aujay, M ;
Wang, XV ;
Ellis, D ;
Becker, MF ;
Lasut, AL ;
George, HJ ;
Spalding, DR ;
Hollis, G ;
Abremski, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2475-2484
[2]  
*BHIVA, 2001, HIV MED, V2, P276
[3]   Predicting the unpredictable: Transmission of drug-resistant HIV [J].
Blower, SM ;
Aschenbach, AN ;
Gershengorn, HB ;
Kahn, JO .
NATURE MEDICINE, 2001, 7 (09) :1016-1020
[4]   Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection [J].
Brenner, BG ;
Routy, JP ;
Petrella, M ;
Moisi, D ;
Oliveira, M ;
Detorio, M ;
Spira, B ;
Essabag, V ;
Conway, B ;
Lalonde, R ;
Sekaly, RP ;
Wainberg, MA .
JOURNAL OF VIROLOGY, 2002, 76 (04) :1753-1761
[5]   Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies [J].
Egger, M ;
May, M ;
Chêne, G ;
Phillips, AN ;
Ledergerber, B ;
Dabis, F ;
Costagliola, D ;
Monforte, AD ;
de Wolf, F ;
Reiss, P ;
Lundgren, JD ;
Justice, AC ;
Staszewski, S ;
Leport, C ;
Hogg, RS ;
Sabin, CA ;
Gill, MJ ;
Salzberger, B ;
Sterne, JAC .
LANCET, 2002, 360 (9327) :119-129
[6]  
Greenberg ML, 2002, ANTIVIR THER, V7, pS14
[7]  
Günthard HF, 1999, J VIROL, V73, P9404
[8]   Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples [J].
Hertogs, K ;
Bloor, S ;
Kemp, SD ;
Van den Eynde, C ;
Alcorn, TM ;
Pauwels, R ;
Van Houtte, M ;
Staszewski, S ;
Miller, V ;
Larder, BA .
AIDS, 2000, 14 (09) :1203-1210
[9]   Antiretroviral drug resistance testing in adult HIV-1 infection -: Recommendations of an International AIDS Society-USA panel [J].
Hirsch, MS ;
Brun-Vézinet, F ;
D'Aquila, RT ;
Hammer, SM ;
Johnson, VA ;
Kuritzkes, DR ;
Loveday, C ;
Mellors, JW ;
Clotet, B ;
Conway, B ;
Demeter, LM ;
Vella, S ;
Jacobsen, DM ;
Richman, DD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (18) :2417-2426
[10]   Resistance profiles in patients with viral rebound on potent antiretroviral therapy [J].
Lepri, AC ;
Sabin, CA ;
Staszewski, S ;
Hertogs, K ;
Müller, A ;
Rabenau, H ;
Philips, AN ;
Miller, V .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) :1143-1147